FDA Brief

Warning letters Drugs

FDA warning letter to

Buzzagogo, LLC

High riskIssued Jan 18, 2023Posted Jan 24, 2023Center for Drug Evaluation and Research | CDER

Buzzagogo's Allergy Bee Gone for Kids nasal swab is an unapproved new drug contaminated with Bacillus bacteria.

What happened

FDA reviewed Buzzagogo's website in August 2022 and found claims showing "Allergy Bee Gone for Kids" is intended as a drug; no FDA-approved application was in effect. FDA laboratory analysis of lot 2006491 found Bacillus contamination, including B. cereus, in a nasal swab product directed for young children. After a May 24, 2022 teleconference, the company recalled that lot on June 7, 2022.

What FDA found

  1. The product is an unapproved new drug because its labeling claims it treats allergy and cold symptoms, but no FDA-approved application is in effect.

    sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  2. The labeling claims make it a drug intended to treat disease or affect body structure or function.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  3. It is a new drug not generally recognized as safe and effective for its labeled uses.

    section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  4. Lot 2006491 was adulterated because it contained Bacillus contamination, including B. cereus, described as a filthy, putrid, or decomposed substance.

    section 501(a)(1) of the FD&C Act, 21 U.S.C. 351(a)(1)
  5. Introducing or delivering the product into interstate commerce violates the FD&C Act.

    section 301 of the FD&C Act, 21 U.S.C. 331

What FDA wants

FDA asks the company to provide a written response within 15 working days, including contract manufacturer names and addresses, an independent manufacturing assessment, a microbial risk assessment, batch investigations, microbial release specifications, test methods, and retain-sample results. If corrective action cannot be completed in that time, the company must explain why and give a completion date.

Who should pay attention

  • brands selling children's nasal or homeopathic drug products
  • contract manufacturers and testing labs for nasal drugs
  • retailers and distributors handling recalled lots

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk